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Abstract
Background: Erysipelas is a common and severe infection where the aetiology and optimal management is not
well-studied. Here, we investigate the clinical features, bacteriological aetiology, and treatment of erysipelas.
Methods: Episodes of erysipelas in a seven-years period in our institution were studied retrospectively using a
pre-specified protocol and is presented with descriptive and comparative statistics.
Results: 1142 episodes of erysipelas were identified in 981 patients. Patients had a median age of 61 years, 59 % were
male, a majority had underlying diseases or predisposing conditions, and the leg was most often affected. Wound
cultures were taken in 343 episodes and 56 grew group A streptococci (GAS), 53 grew group G streptococci (GGS), 11
grew group C streptococci (GCS), and 153 grew Staphylococcus aureus. Blood cultures were drawn in 49 % of episodes
and 50 cultures were positive with GGS as the most common finding (21 cultures) followed by GAS in 13, group B
streptococci in 5, S. aureus in 4, and GCS in 3 cultures. In 45 % of episodes, patients received antibiotics with activity
against S. aureus.
Conclusions: GGS is the most common streptococcus isolated in erysipelas and the role of S. aureus in erysipelas
remains elusive.
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Background
Erysipelas is a common skin infection causing significant
morbidity in patient which often have underlying condi-
tions [1, 2]. The clinical picture is characterized by an
inflammatory reaction of the upper dermis with a sharp
demarcation of the erythema. Occasionally, a primary
lesion such as a wound or skin crack is present. Associ-
ated symptoms and signs are nausea, pain, and fever [3].
Erysipelas cannot always be distinctly separated from
cellulitis, which refers to a deeper soft tissue infection
involving the dermis and subcutaneous fat, or from more
severe conditions such as necrotizing fasciitis [4, 5]. Some
clinicians use the term erysipelas only for facial cuta-
neous infections whereas yet others use the term ery-
sipelas also to describe cellulitis [5]. The diagnosis of
soft tissue infections relies on the clinical picture and
on the diagnostic traditions, making comparisons between
studies problematic.
Despite erysipelas being common, and the skin is ac-
cessible for bacteriological sampling, the aetiology of
erysipelas is still not firmly established. Most authors
agree that beta-haemolytic streptococci (BHS) are causa-
tive pathogens, though such bacteria are typically iso-
lated only from a minority of patients [4]. Cultures from
needle aspirates or punch biopsies of the inflamed skin
identify pathogenic bacteria in a minority of cases [6–9]
and cultures from primary lesions have a similar sensi-
tivity. In three prospective studies on erysipelas, group A
streptococci (GAS) were identified in 15–22 %, group G
streptococci (GGS) in 3–12 %, and Staphylococcus
aureus in pure culture in 7–18 % of cases [6, 10, 11].
In support for BHS aetiology of erysipelas, one study using
immunofluorescence identified BHS in 19, of which 13
were GAS, of 27 erysipelas cases [12]. Serological studies
have also been performed and support BHS aetiology in a
share of the cases but results have been somewhat con-
flicting [6, 7, 12, 13]. Bacteraemia is rare in erysipelas and
current guidelines do not recommend blood cultures to
be taken in uncomplicated cases [4]. In a recent systematic
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review of five studies on erysipelas, 28 of 607 blood cul-
tures (4,6 %) were positive. Of the positive cultures,
13 grew GAS, 8 other BHS, 4 S. aureus, and 3 gram-
negatives [14].
Traditionally, BHS have been characterized by grouping
and the group is not always in concordance with the
species. Importantly, BHS of groups C and G strepto-
cocci (GCS and GGS) can be of different species, but
lately it has become apparent that human pathogenic
GGS are nearly always Streptococcus dysgalactiae sub-
species equisimilis (SDSE) [15]. GCS are also commonly
SDSE but Streptococcus equi subspecies zooepidemicus
of group C also cause human infections [16]. Human
pathogenic GAS (which is nearly always Streptococcus
pyogenes) and SDSE share many important virulence strat-
egies and are both uniformly sensitive to penicillin [17].
The lack of uniform diagnostic criteria for erysipelas
and the lack of a well-supported knowledge of its aeti-
ology are problematic. In particular, the role of S. aureus
in erysipelas is uncertain and many patients with erysip-
elas are probably therefore treated with antibiotics with an
unnecessary broad spectrum. In this retrospective analysis,
we present the clinical and microbiological findings from
patients with erysipelas treated at our clinic between 2007
and 2013.
Methods
Cases of patients ≥18 years of age registered with a
ICD-10 diagnosis of erysipelas (A46.9) or cellulitis
(L03) at the Department of Infectious Diseases at Skåne
University Hospital, Lund, Sweden from January 1st 2007
to December 31st 2013 were identified. Both hospitalized
and outpatients were included. The University Hospital of
Lund serves approximately 200 000 inhabitants living in
the surrounding area. The medical records were reviewed
according to a pre-specified protocol. Microsoft Excel
2008 (Microsoft Corporation) was used for data collec-
tion and descriptive analyses and Graph Pad Prism 6.0a
(GraphPad software) for statistical analyses. The Ethics
Committee of Lund University, Sweden approved of the
study (2011/672). The medical records regarding episodes
of erysipelas between January 2007 and December 2010
had been reviewed in a previous set and an analysis of risk
factors for recurrence has already been studied [2].
Epidemiological and clinical parameters recorded in-
cluded age, sex, hospital stay, relapses, cases with out-
patient and inpatient treatment respectively, localisation
of erysipelas, antibiotic treatment and duration, the cri-
teria severe inflammatory response syndrome (SIRS)
[18], CRP, creatinine, and platelet levels on admission.
Underlying disease was classified as cardiovascular dis-
ease, autoimmune/systemic inflammatory disease, cancer,
diabetes mellitus, chronic obstructive pulmonary disease
(COPD), or kidney disease. Predisposing factors were
defined as having wounds, previous radiation therapy,
local operation (any kind), peripheral venous insufficiency,
polyneuropathy, lymphedema, or skin disease. Microbio-
logical results from swabs and from blood cultures were
collected from the accredited Laboratory for Medical
Microbiology in Lund. Isolates of BHS had previously
been grouped by the routine laboratory. We subjected
BHS isolates from blood to matrix-assisted laser desorp-
tion ionization time-of-flight mass spectrometry (MALDI-
TOF) with the direct transfer method and analysis with
Ultraflextreme MALDI-TOF MS (Bruker Daltonics, Bre-
men, Germany), using the Biotyper version 3.0 software
without modifications.
Statistics
Fisher’s exact test and Mann Whitney test were utilized
to detect statistically differences between different groups
depending on the lighted variables. Significance was de-
fined as a P-value less than 0.05.
Results
Patients
1142 episodes of erysipelas in 981 patients were re-
corded and studied. During the same time period 188
episodes of cellulitis were recorded. The diagnosis of
“cellulitis” is in our Department used to describe a
deeper type of infection and these cases were not further
studied. The patients were predominately male (59 %) and
the median age was 61 (range 18–99 years). 44 % of pa-
tient had an underlying disease and 78 % had one or sev-
eral predisposing factors. Only 13 % of the patients had
neither predisposing factors nor an underlying disease
(Table 1). In 567 episodes, patients were treated as outpa-
tients and in 575 episodes the patient was admitted. The
median length of stay for admitted patients was 5 days
(range 1–34 days). 745 episodes were first-time infections
and 397 represented relapses. The most common location
of erysipelas was in the leg (66 %) followed by arm, and
face (Table 2). 39 % of all cases fulfilled the criteria for
SIRS, and median CRP and WBC count upon evaluation
was 76 and 10.6 respectively (Table 2).
Table 1 Characteristic of 981 patients with erysipelas
Clinical characteristic No. patients (%)
Age, median (range) 61 (18–99)
Male sex 580 (59 %)
Underlying disease 433 (44 %)
Predisposing factor 766 (78 %)
Both underlying disease and predisposing factor 346 (35 %)
Neither underlying disease nor predisposing factor 128 (13 %)
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Wound cultures
A wound culture was taken in 343 of the 1142 episodes
and of the cultures 248 (72 %) grew bacteria. Patients
from which such cultures were taken were significantly
older (63 vs 60 years), were more often admitted, and a
had more often predisposing conditions or underlying
diseases as compared to cases where no skin culture was
taken. Of the positive cultures 56 (23 %) grew GAS of
which 37 cultures were monocultures, 53 (21 %) grew
GGS of which 15 cultures were pure, 11 grew a BHS of
group C (GCS) of which 3 were in pure cultures, and
153 (62 %) grew S. aureus of which 85 cultures were
pure (Fig. 1). None of the S. aureus isolates were resist-
ant to methicillin. Sixteen cultures were polymicrobial
and bacteria were not species determined and another
15 cultures (6 %) grew Pseudomonas aeruginosa. En-
terococci were encountered in 10 cultures (4 %) and
enterobacteriacae in 9 cultures (4 %) (Fig. 1).
Notably, a significantly higher proportion of GGS and
GCS than GAS isolates were found in co-cultures with
S. aureus (72 vs 30 %, p < 0.0001 with Fischer’s exact test
for a difference between GGS and GAS). Three patients
with GAS and three patients with GGS in co-cultures
with S. aureus had bacteraemia with the respective BHS.
Blood cultures
Blood cultures were collected in 555 episodes (49 %). Of
obtained cultures, 492 (89 %) were negative, 13 (2 %)
were considered to be contaminated (finding of coagu-
lase negative staphylococci in one or two flasks), and 50
(9 %) were positive. Patients subjected to blood culturing
were significantly more likely to fulfil criteria for SIRS
(55 vs 23 %), to be admitted (79 vs 23 %), to have under-
lying diseases (52 vs 41 %) particularly diabetes mellitus
(18 vs 11 %), and to be of male sex (63 vs 57 %) as com-
pared to the cases where no blood culture was taken. In
addition, patients where blood cultures were taken had a
significantly higher mean CRP (91 vs 57 mg/L) and were
more often subjected to wound cultures (64 vs 25 %).
The results of the blood cultures are shown in Fig. 2.
The most commonly isolated bacterium in blood was
GGS (21 cultures). The GGS isolates as well as the three
GCS isolates were determined to be Streptococcus dys-
galactiae using MALDI-TOF MS. GAS (confirmed to
be Streptococcus pyogenes with MALDI-TOF MS) was
isolated in 13 cases, GBS (confirmed to be Streptococ-
cus agalactiae with MALDI-TOF MS) in five cases,
and S. aureus in four cases. Patients with S. pyogenes
bacteraemia were younger than patients with SDSE
bacteraemia (63 vs 73 years, p = 0.02 for difference
using Wilcoxon’s rank sum test), but otherwise clin-
ical parameters were similar. Patients with S. aureus
bacteraemia had septic arthritis, cellulitis, a deep soft
tissue infection, and infective endocarditis respect-
ively. In six episodes with findings of GAS in blood, a
cutaneous swab also grew GAS and in five episodes
with findings of GGS in blood the cutaneous swab
also grew GGS. Of the four patients with S. aureus in
blood cultures, three had findings of S. aureus from
wound cultures.
Taken together, the results from the microbiological
analyses imply GAS as the causative organism in 61
Table 2 Characteristic of 1142 episodes of erysipelas
Site of infection
Leg 771 (68 %)
Arm/hand 136 (12 %)
Face 107 (9 %)
Other 128 (11 %)
Previous erysipelas 397 (35 %)
Episodes with SIRS (≥2points) 444 (39 %)
CRP (mg/L), mean (range) 76 (<0.6–520)
Leukocyte count (X10^/L), mean (range) 10,6 (2–326)
Temperature C°, mean (range) 37, 3 (35.1–41)
Days of hospitalization, median (range) 5 (1–34)
Days of antibiotic treatment, median (range) 11 (1–29)
Outpatient treatment 567 (50 %)
Initial treatment with iv antibiotics 713 (62 %)
Definite treatment
Penicillin 569 (50 %)
Antibiotic effective against S. aureus 461 (40 %)
Allergy to penicillin 112 (10 %)
Fig. 1 Number of skin swabs and wound cultures positive for
different possible pathogens is given. The black part of the bar
represents a monoculture of the respective pathogen whereas the
grey part of the bar represents culture where more than one
bacterial species was identified
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cases, GGS or GCS in 82 cases, and GBS in 9 cases.
When comparing episodes where GAS was implied with
those where GCS/GGS were implied, the only statisti-
cally significant differences were that GCS/GGS episodes
more commonly affected male patients (74 vs 57 %,) and
were more likely to have recurrence (35 vs 18 %).
Treatment and outcome
In 643 episodes (56 %), empirical treatment was initi-
ated with penicillin of which 435 received intravenous
penicillin G. In 131 episodes the initial treatment was
cloxacillin or flucloxacillin, in 195 episodes a beta-lactam
antibiotic with broad spectrum, in 150 episodes clindamy-
cin, and other antibiotics were given initially in 22 epi-
sodes. For definite treatment, defined as the antibiotic
prescribed when the patient left the hospital, penicillin
was used in 567 (55 %) cases and antibiotics effective
against methicillin susceptible S. aureus (MSSA) was used
in 463 (45 %) cases. Patients allergic to penicillin were ex-
cluded from this analysis. Median duration of treatment
was 11 days (range 1–34).
Of cases with S. aureus in a microbiological specimen,
64 % received treatment with an antibiotic effective
against MSSA compared to 36 % in the group where
no microbiological evidence for S. aureus was present
(p = 0.0001). Patients receiving an antibiotic effective
against MSSA as definite treatment were more likely to
have an underlying condition (82 vs 74 %, p = 0.001).
Interestingly, patients with a previous episode of erysipelas
was more likely to receive penicillin (62 vs 52 %, p = 0.003)
whereas those receiving penicillin or MSSA effective
treatment had similar risk of recurrence. Outcome was
generally favourable and only four fatalities were recorded.
Twenty-five patients received secondary prophylaxis with
penicillin.
Discussion
Microbiological methods to determine the aetiology of
erysipelas have low sensitivity and treatment is in most
cases empirical. Previous studies have mostly been pro-
spective and relatively small. The present retrospective
study is by far the largest presented and it confirms
some of the previously reported findings whereas it con-
trasts to earlier notions on the relative importance of
GAS and GCS/GGS. This study has several shortcom-
ings. The retrospective nature does not allow us to spe-
cify how patients should be cultured or managed. We
chose to include patients where the attending physician
had made a diagnosis of erysipelas. Likely, different phy-
sicians have different criteria and the tradition of our
clinic probably also affect the likelihood of the diagnosis.
The study was carried out in a single institution to
which a selected patient population might seek care,
though our hospital is the only one serving the popula-
tion. Probably, patients coming to our institution are
more likely to be severely ill and have underlying condi-
tions than patients coming to a primary care unit. Gen-
eralizations made from the present results should be
done with care.
As in previous studies, we find that patients with ery-
sipelas are likely to be male, around 60 years-old, and
have underlying diseases and predisposing conditions.
Moreover, we find that blood culture positivity is rare in
erysipelas though our figure (50 positives out of 555 cul-
tures) is significantly higher than those reported previ-
ously [14] (28 positives of 607 cultures, p = 0.003 for a
difference using Fischers exact test). Blood cultures are
not recommended in uncomplicated cases of erysipelas
[4] but in a significant share of episodes (49 %) reported
here a blood culture was drawn. Those subjected to
blood culturing were significantly more ill than those
who were not blood cultured but the sensitivity of blood
cultures is still very low. Of our episodes, we found evi-
dence for a BHS involvement in 13 % which is somewhat
lower than in previous studies which have been pro-
spective with more diagnostic efforts [6, 10, 11]. The
relative contribution of different groups of BHS is differ-
ent in this study compared to previous reports of erysip-
elas [6, 10, 12]. Importantly as opposed to previous
studies, GGS was the most common BHS isolated from
blood and all these isolates as well as those of GCS were
shown to be Streptococcus dysgalactiae of which sub-
species equisimilis is the only known human pathogen
[16]. Thus, it appears that SDSE is a common and
important pathogen in erysipelas. Indeed, several
Fig. 2 Number of blood cultures positive for different bacterial
species. For SDSE, the black part of the bar represents GGS and the
grey part represents GCS. For S. pyogenes, the black part of the bar
represents monocultures whereas the grey part represents a culture
which also grew P. aeruginosa and coagulase negative staphylococci
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authors have reported an increase in severe infections
with SDSE [15, 19]. An older Swedish study and sev-
eral recent reports on cellulitis have also implicated
GGS or SDSE as pathogens frequently causing erysip-
elas or cellulitis [11, 20–22]. The finding that patients
with GCS/GGS aetiology were more prone to experi-
ence recurrence is very interesting and in line with a
number of reports describing that recurrent bacter-
aemia is a particular feature of SDSE [23–26]. Indeed,
an increase tendency for recurrence in GGS cellulitis
as compared to GAS cellulitis was very recently demon-
strated [22]. Possibly, GCS/GGS aetiology should be con-
sidered when a decision about secondary prophylaxis is
made. In line with this argument, anal carriage of GGS
have previously been implicated as a possible mechanism
for GGS recurrence in erysipelas [27]. It is also intriguing
that GGS, more often than GAS, was found together with
S. aureus in wound cultures and this likely reflects differ-
ences in virulence and colonization strategies of the bac-
teria. It can be speculated that GGS is more likely to
infect a person if there is a pre-existing wound colonized
with S. aureus though such a speculation would need con-
firmatory studies to be supported.
As compared to earlier studies a higher proportion of
wound cultures in our study grew S. aureus [6, 10, 11] and
if this finding should be interpreted as S. aureus being a
common causative pathogen is not clear. It was evident,
however, that patients with S. aureus in wound cultures
were more likely to receive an antibiotic effective against
MSSA, suggesting that clinicians perhaps use positive S.
aureus cultures as a basis for decision-making. S. aureus
was found in four blood cultures but upon examination of
the medical records it became evident that at least three of
them had other diagnoses that should have excluded them
from a diagnosis of erysipelas. Such a selected post-
analysis is problematic and points to the weakness in using
diagnostic codes for selection of patients. However, our
results indicate that S. aureus bacteraemia is very un-
common in erysipelas. We cannot exclude, however, that
patients with soft tissue infections and S. aureus bacter-
aemia received a diagnosis of cellulitis instead of erysipelas
based on bacteriology rather than the nature of the soft
tissue infection. It thus remains difficult to draw definite
conclusions on the role of S. aureus in erysipelas. In gen-
eral, the antibiotic treatment of erysipelas in our institu-
tion was directed towards a staphylococcal aetiology in
large proportion of cases and this is not in line with
current recommendations [4]. The median length of anti-
biotic treatment was 11 days, which is also longer than the
suggested standard treatment time (5 days) [4].
Conclusions
Our study indicates that GCS/GGS is an important
aetiological factor in erysipelas and underlines the need
for novel diagnostic procedures to better guide antibiotic
therapy.
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